Endocrinology
Conference Coverage
T2D treatments create tension between glycemic and cardiovascular goals
Recent society guidelines clash on whether metformin or newer drug classes should start first when treating patients with type 2 diabetes.
Conference Coverage
Empagliflozin cut PA pressures in heart failure patients
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time....
Conference Coverage
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
Conference Coverage
Higher glycemic time in range may benefit T2D patients
A post hoc analysis linked greater blood-glucose time in range with fewer hypoglycemic, microvascular, and major adverse cardiac events in T2D...
Conference Coverage
Exercise cuts diabetes death risk by a third in two studies
Results of two new studies provide further evidence that exercise reduces all-cause and cardiovascular mortality in those with type 2 diabetes.
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
Feature
More U.S. states cap insulin cost, but activists will ‘fight harder’
Drugmakers and health insurers have not legally challenged state laws capping out-of-pocket insulin costs; still, such attempts to make insulin...
From the Journals
Obesity boosts risks in COVID-19 from diagnosis to death
Excess pounds are linked to excess infection, hospitalization, ICU admission, and mortality.
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.